/A
Phase 1
- Conditions
- MedDRA version: 18.0Level: PTClassification code 10054935Term: Aicardi's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Registration Number
- EUCTR2014-002710-23-FR
- Lead Sponsor
- ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways and gene targets are explored in EUCTR2014-002710-23-FR for Aicardi's syndrome (MedDRA 10054935)?
How does EUCTR2014-002710-23-FR address unmet therapeutic needs in Aicardi's syndrome compared to current experimental strategies?
Which biomarkers predict therapeutic response in the EUCTR2014-002710-23-FR Phase I Aicardi's syndrome trial?
What are the potential adverse events and safety monitoring protocols in the EUCTR2014-002710-23-FR Phase I trial for Aicardi's syndrome?
What are the related compounds or combination therapies being investigated for Aicardi's syndrome alongside EUCTR2014-002710-23-FR?